ACVR2B (ACE-031) Bio Peptide

Product Description

ACVR2B, commonly known as ACE-031, is a recombinant fusion protein designed to inhibit myostatin, a natural protein in the body that limits muscle growth. Developed through a collaboration between Acceleron Pharma and Shire, ACE-031 was initially researched as a potential treatment for muscle-wasting diseases such as muscular dystrophy.

As a bioactive peptide, ACE-031 has drawn attention in the performance and bodybuilding world for its muscle-building potential, acting as a myostatin blocker that essentially “removes the brakes” on muscle growth.

How It Works:

ACE-031 works by binding to and neutralizing myostatin, a protein that tells your body to limit muscle development. By inhibiting myostatin, ACE-031 increases muscle fiber size and encourages lean tissue growth, making it a highly anabolic compound.

It also binds to other ligands like activins, contributing to enhanced muscle mass, improved muscle strength, and potentially better bone density.

Potential Benefits:

• Significant increase in lean muscle mass

• Enhanced muscle density and size

• Reduced muscle wasting (catabolism)

• Improved recovery and physical performance

• Potential benefits for bone health

Key Characteristics:

• Injectable bio-peptide, not orally active

• Directly targets the myostatin/activin pathway

• Very powerful anabolic effect—used in small doses

• Not a steroid, SARM, or hormone

• Effects can last weeks from a single dose